{"filings":[{"id":871036,"accession_number":"0001628280-26-041069","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2026-06-05T12:45:47+00:00","items":["5.07"],"status":"ready","headline":"Cibus stockholders elect nine directors and ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine board nominees (Mark Finn, Peter Beetham, Kimberly A. Box, Jean-Pierre Lehmann, August Moretti, Gerhard Prante, Rory Riggs, Thomas Urban, Craig Wichner) were elected with substantial support.","Advisory say-on-pay approved with 22,117,686 votes for, 167,944 against, 403,113 abstain.","Ratification of BDO USA, P.C. as independent auditor for 2026 passed with 53,014,318 votes for, 36,870 against.","Approximately 69.52% of outstanding shares were represented at the meeting, forming a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442718,"accession_number":"0001628280-26-035105","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2026-05-14T20:11:14+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cibus Q1 net loss narrows to $21.2M; Rice HT U.S. launch pushed to 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.2M ($0.33/share) vs $49.4M ($1.34) in Q1 2025; no goodwill impairment this quarter.","Cash at $30.3M; net cash usage guidance of ~$30M or less in 2026.","Rice HT program: U.S. launch rescheduled to 2029 due to herbicide registration delay; LATAM launch still targeted for 2027.","Q1 revenue increased YoY; R&D down 26% to $8.7M, SG&A down 48% to $5.1M on cost cuts.","Raised ~$37.3M in two equity offerings YTD 2026; Thomas Urban appointed to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":1681000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94847,"accession_number":"0001628280-26-024746","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cibus appoints Thomas Urban to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Thomas Urban, founder of Agribusiness Advisors, effective April 7, 2026.","Urban previously served as CEO of CellFor, executive at Pioneer Hi-Bred, and began career at Goldman Sachs.","Annual director compensation: $60,000 cash retainer plus $90,000 in equity, prorated for service through next annual meeting.","No material arrangements or transactions requiring disclosure under Item 404(a) were identified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107520,"accession_number":"0001193125-26-127706","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cibus raises ~$13.5M in public offering of 6.98M shares at $2.15/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten public offering of 6,976,744 shares of Class A common stock at $2.15 per share.","Net proceeds estimated at $13.5M ($16.0M if underwriter's over-allotment option exercised in full).","BTIG, LLC serving as sole underwriter with a 7.0% discount and up to $150,000 expense reimbursement.","Offering expected to close March 27, 2026; 30-day option for additional 1,046,511 shares.","Lock-up agreements for 60 days for directors, executive officers, and company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107519,"accession_number":"0001628280-26-018716","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cibus Q4 loss $31.9M; cash $9.9M; Jan 2026 offering $22.3M; exploring strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $9.9M at Dec 31, 2025; with $19.8M net Jan 2026 offering, runway into late Q3 2026.","Q4 net loss $31.9M ($0.59/share) vs $25.8M a year ago; includes $9.1M non-cash impairment of Roseville facility.","Raised $22.3M gross ($19.8M net) in January 2026 public offering to fund rice trait advancement.","Board evaluating strategic alternatives to maximize shareholder value; no definitive actions announced.","Rice program on track for 2027/2028 commercial launches; sustainable ingredients received first customer payment in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107518,"accession_number":"0001193125-26-030591","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cibus announces public offering of 13.3M shares at $1.50; board members buy 1M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 13,333,333 shares of Class A common stock at $1.50 per share; BTIG sole underwriter.","Net proceeds estimated at ~$17.8M (or ~$20.5M if underwriter option exercised in full).","Board of directors purchasing 1,000,000 shares in the offering at the same public price.","Underwriter granted 30-day option for up to 1,999,999 additional shares.","Company and insiders subject to 60-day lock-up post-offering; expected close Jan 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107517,"accession_number":"0001193125-26-027229","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cibus Updates Business Outlook in 8-K, Projects >$200M Annual Royalties from Rice Traits","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cibus estimates over $200 million potential annual addressable royalties from Rice herbicide tolerance traits in the US and Latin America.","Company reduced workforce by approximately 34 full-time employees by December 31, 2025, to streamline focus on Rice program.","Anticipates annual net cash usage of $30 million or less during 2026 following cost reduction actions.","Biofragrance products program could reach $20-40 million annual revenue over a long-term horizon, with initial payments received in 2025.","EU trilogue on New Genomic Techniques positively concluded in December 2025, creating a regulatory path for gene-edited plants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107516,"accession_number":"0001628280-26-000957","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cibus purchases 60,088 shares from employee Anthony Moran at $0.0001/share","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Purchased 60,088 shares of Class A common stock from employee Anthony Moran at $0.0001 per share.","Total consideration approximately $6; transaction approved by board and effective December 31, 2025.","No additional context provided for the nominal-price repurchase.","Shares repurchased represent a very small fraction of outstanding stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123872,"accession_number":"0001628280-25-052018","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cibus Q3 net loss $24.3M; $23.9M cash; signs 7 Rice customers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.3M ($0.44/share) vs $201.5M year-ago which included $181.4M goodwill impairment.","Cash $23.9M at Sep 30; expects to fund into early Q2 2026 without new financing.","Signed 7 Rice customer agreements; estimated 5-7M addressable acres, >$200M potential annual royalty.","Completed pre-commercial biofragrance pilot; first payment received in Q4; commercial expansion targeted 2026.","Targeting $30M annual net cash use by 2026; appointed Kimberly Box and Craig Wichner to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":2582000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123871,"accession_number":"0001628280-25-051101","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cibus appoints Craig Wichner to Board of Directors effective Nov 5, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Craig Wichner as Board member effective November 5, 2025; also serves on Strategy Committee.","Wichner is founder and managing partner of Farmland LP, a farmland investment firm with >$350M AUM and 19,000 acres.","Annual director compensation: $60,000 cash retainer plus $90,000 equity grant, prorated for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140542,"accession_number":"0001193125-25-213340","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cibus appoints Carlo Broos as permanent CFO; base salary €440,000","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Broos served as Interim CFO since Oct 1, 2024; previously SVP of Finance.","Base salary €440,000, eligible for discretionary annual bonus and equity grants.","At-will employment; severance of 18 months base salary for without-cause/good-reason termination.","Change-in-control severance: 24 months base salary, lump-sum bonus, full equity vesting.","Broos must work at San Diego office at least one week per month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140541,"accession_number":"0001193125-25-204988","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cibus appoints Kimberly A. Box to board; adds experience from Hewlett Packard and Gatekeeper Innovation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kimberly A. Box, 65, appointed to board effective September 11, 2025.","She will serve on Compensation, Nominating/Governance, and the special committee evaluating strategic alternatives.","Previously President/CEO of Gatekeeper Innovation and 29-year HP executive (VP Global IT Services until 2009).","Annual director compensation: $60,000 cash retainer (semi-annual) plus $90,000 equity grant, prorated for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140540,"accession_number":"0001705843-25-000010","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cibus Q2 net loss narrows to $26.6M; cash runway into Q2 2026; Rice trait commercialization on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $26.6M ($0.61 per share) vs $28.5M ($1.14) YoY; R&D $12.2M, SG&A $6.6M, both down on cost cuts.","Cash $36.5M at June 30; raised $27.5M gross from June offering; expects funding into Q2 2026.","Streamlining targets annual cash usage ~$30M by 2026; focused on Rice herbicide tolerance and partner-funded programs.","Rice HT1/HT3 traits on track for Latin America launch 2027, US 2028; signed collaboration with Colombia's Semillano; delivered HT3 lines to US customer.","Sustainable ingredients program on track for nominal 2025 revenues; regulatory wins: Ecuador cleared HT1/HT3 as non-GMO, USDA deregulated HT2 canola."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":1967000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140539,"accession_number":"0001193125-25-163439","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Cibus cuts 34 jobs (~$0.5M severance charge) to streamline focus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved reduction of approximately 34 full-time employees on July 21, 2025.","Workforce reduction expected to be completed by December 31, 2025.","Estimated $0.5 million one-time charges for accrued vacation and severance in Q3 2025.","Part of previously announced shift to nearest-term commercial opportunities.","Affected employees notified on July 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158243,"accession_number":"0001193125-25-137129","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cibus prices 15.7M-share public offering at $1.75/share; expected close June 9","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Securities Purchase Agreements for 15,714,285 shares at $1.75/share in registered public offering.","Offering includes pre-funded warrants for certain purchasers; proceeds for weed management trait development in Rice and working capital.","Company and executive officers/directors subject to 60-day lock-up on stock sales.","Placement agent A.G.P. receives 7.0% fee on sales to certain purchasers, 2.0% on others, no fee on Chairman's shares.","Closing expected June 6 for some purchasers and June 9 for the Chairman; Placement Agency Agreement executed June 5."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158242,"accession_number":"0001193125-25-134948","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cibus streamlines focus on Rice weed traits, targets $30M annual cash burn by 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Focusing on HT1 and HT3 herbicide tolerance traits in Rice for commercial launch in Latin America (2027-2028) and U.S. mid-south (2028).","Plans cost reductions to reduce annual net cash burn to ~$30M by 2026, including rationalizing headcount and non-core facilities.","Regulatory wins: California approval for gene-edited Rice field research (Feb 2025); USDA-APHIS designated two Canola traits as not regulated (Apr 2025).","Ecuador determined HT1/HT3 Rice traits equivalent to conventional breeding (Apr 2025), important as country prohibits GMO planting.","Partner-funded sustainable ingredients program targeting nominal revenues in 2025 with commercial expansion in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158241,"accession_number":"0001628280-25-027958","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Stockholders approve Cibus 2025 Employee Stock Purchase Plan; 326,384 shares reserved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders at May 22, 2025 annual meeting approved adoption of Cibus 2025 ESPP.","Initial 326,384 shares of Class A common stock reserved; annual auto-increase through 2035.","ESPP allows eligible employees to buy stock at minimum 85% of lower of FMV on offering or purchase date.","Payroll deductions up to 10% of compensation; annual purchase limit of $25,000 in FMV.","Plan includes both 423 and Non-423 components for U.S. and foreign employees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158240,"accession_number":"0001628280-25-027627","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cibus shareholders approve warrant repricing, change-of-control issuance, and up to 9.04M share dilution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected; advisory say-on-pay passed with 13.2M votes for.","Ratification of BDO USA as auditor and 2025 Employee Stock Purchase Plan both approved.","Issuance of up to 9,040,000 shares upon exercise of warrants (Jan 2025 SPA) approved.","Repricing of certain warrants held by director Rory Riggs approved (13.1M for, 468K against).","Issuance of shares upon future exercise of Riggs warrants deemed a change of control approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158239,"accession_number":"0001628280-25-023826","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cibus Q1 net loss $49.4M; cash $23.6M into Q3; evaluates strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $49.4M ($1.34 per share) vs $27.0M a year ago; includes $21.0M non-cash goodwill impairment.","Cash and cash equivalents $23.6M as of March 31, 2025; expects to fund operations into Q3 2025 without new financing.","Board and financial advisor evaluating a full range of strategic alternatives to maximize shareholder value.","Regulatory wins: Ecuador deemed HT1/HT3 rice traits equivalent to conventional; USDA-APHIS classified two canola disease resistance traits as not regulated.","Rice trait commercialization on track for 2027; customer germplasm integration underway in North and South America."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":1034000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176614,"accession_number":"0001628280-25-015155","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K/A","filed_at":"2025-03-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cibus discloses $650K base salary for Interim CEO Dr. Peter Beetham","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary of $650,000 approved March 24, 2025, effective February 24, 2025.","Compensation set in connection with Beetham's appointment as Interim CEO of Cibus.","Original 8-K filed Feb 28, 2025, disclosed Beetham as Interim CEO; this amendment adds salary terms.","No other changes to the original filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176617,"accession_number":"0001628280-25-014118","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cibus Q4 2024 net loss $25.8M; cash $14.4M; reviews strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $25.8M vs $277.2M in Q4 2023 (prior-year includes $249.4M goodwill impairment); EPS -$0.87 vs -$12.59.","Cash $14.4M at Dec 31; after Jan 2025 $21.4M net offering, expects runway into late Q3 2025.","Board, with advisor, evaluating full range of strategic alternatives to maximize shareholder value.","Business progress: EU Trilogue advanced; CA Rice Commission approved gene-edited Rice field trial; four Rice seed customer agreements.","Cost-saving initiatives targeting $10M annualized run-rate, ~20% monthly cash use reduction; facility consolidation on track."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176616,"accession_number":"0001628280-25-008888","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cibus CEO Rory Riggs resigns; President Peter Beetham named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rory Riggs resigns as CEO, remains Chairman of the Board.","President and COO Peter Beetham appointed Interim CEO effective immediately.","Board will conduct a search for a permanent CEO, considering external and internal candidates.","Beetham co-founded Cibus Global and has over 30 years of agricultural technology experience.","Riggs cites the company's transition from development to commercial as timely for succession."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176615,"accession_number":"0001193125-25-010355","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cibus raises ~$22.6M in registered direct offering; CEO Riggs participates at $2.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company sells 4,340,000 shares at $2.50 each with common warrants; 4,700,000 pre-funded warrants at $2.4999.","CEO Rory Riggs among purchasers; 60-day lock-up for executives and directors.","Existing investor warrants amended: exercise price cut from $10.00 to $2.50; term extended to 5 years post-closing.","Closing expected Jan 24, 2025 for most investors; warrant exercise requires stockholder approval.","A.G.P./Alliance Global Partners acts as sole placement agent with fees of 7% or 2% on proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193460,"accession_number":"0001193125-24-273978","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cibus sets 2025 base salary for Carlo Broos at $320,000","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Compensation Committee approved $320,000 base salary for Carlo Broos effective Dec 3, 2024.","Salary is for the 2025 calendar year and takes effect immediately upon approval.","Approval occurred on December 3, 2024, as reported on Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193459,"accession_number":"0001628280-24-048288","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cibus appoints August Moretti to Board of Directors and Audit Committee effective Nov 18, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["August Moretti, 74, appointed as director and Audit Committee member effective November 18, 2024.","Moretti most recently served as CFO of 4D Molecular Therapeutics until Sept 2023; prior CFO roles at Assertio and Alexza Pharmaceuticals.","He will receive compensation per Cibus Non-Employee Director Compensation Policy and standard indemnification agreement.","No arrangements with other persons exist; no material interest in transactions requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193458,"accession_number":"0001628280-24-046265","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cibus Q3 net loss $201.5M on $181.4M goodwill impairment; cash runway into late Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $201.5M ($7.63/sh) vs $34.5M ($1.59/sh) YoY; includes $181.4M non-cash goodwill impairment.","Cash $28.8M; expects funding into late Q1 2025 without additional financing; board evaluating strategic alternatives.","Initiating $10M annualized cost savings, reducing monthly cash usage ~20%; one-time severance charge in Q4.","Rice platform: agreements with 4 seed companies, successful HT3 field trials, stacked gene-edited trait results.","Soybean platform expected operational by year-end 2024; Sclerotinia resistance field trial positive for second mode of action."],"consensus_eps_estimate":null,"consensus_eps_actual":-10.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":3050000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193457,"accession_number":"0001628280-24-044163","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cibus files updated corporate presentation with no material changes","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished an updated corporate presentation dated October 2024.","No financial results, guidance, or material events were disclosed in the filing.","Presentation intended for discussions with securityholders and other persons.","Specific content of the presentation not available for analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193456,"accession_number":"0001193125-24-239649","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Cibus cuts ~26 jobs, initiates cost reduction actions; expects $0.35M in Q4 charges","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~26 full-time employees approved Oct 16, communicated Oct 18.","Estimated $0.35M one-time costs in Q4 2024 for accrued vacation and severance.","Additional cuts: reduced consultant/third-party spend, organizational restructuring.","Non-renewal of Oberlin facility lease upon expiration in August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193455,"accession_number":"0001193125-24-229522","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cibus appoints Carlo Broos as Interim CFO effective October 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cornelis (Carlo) Broos appointed Interim CFO; previously SVP of Finance since 2024.","Broos joined Cibus in 2011; prior roles at Syngenta and Deloitte; Registered Accountant in Netherlands.","Wade King remains in non-executive role during leave; no new compensatory arrangements for Broos."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209771,"accession_number":"0001193125-24-223303","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cibus partially exercises over-allotment option, issuing 289,953 additional shares at $4.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Representatives exercised option for 289,953 additional shares at $4.00 per share.","Option was part of previously announced underwritten public offering of 3,000,000 shares.","Additional gross proceeds approximately $1.16 million; total offering size now 3,289,953 shares.","Option shares issued under shelf registration statement on Form S-3.","Jones Day provided legal opinion on validity of the Option Shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209770,"accession_number":"0001193125-24-221778","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cibus launches $12M underwritten public offering of 3M shares at $4.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 3,000,000 shares at $4.00 per share; net proceeds ~$11.2M ($12.8M with overallotment).","Underwriters: Roth Capital Partners and A.G.P./Alliance Global Partners; 45-day option for up to 450,000 additional shares.","Offering closed September 19, 2024; 30-day lock-up agreements for company and insiders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209769,"accession_number":"0001193125-24-220705","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cibus announces underwritten offering, updates trait pipeline market estimates for Canola, Rice, Soybean","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Underwritten offering announced; terms not disclosed. Company cites continuing capital resource constraints.","Updated Canola trait pipeline: PSR, Sclerotinia, HT2 targets ~$542M in potential royalties across 78M accessible acres.","Rice weed management platform (HT1/HT3) targets $200M potential royalties on 9M accessible acres in Americas.","Soybean platform expected operational in 2024; Sclerotinia and HT2 traits target $875M potential royalties.","Strategic realignment from Oct 2023 continues; additional cost reduction measures being evaluated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209768,"accession_number":"0001193125-24-204017","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"Cibus CFO Wade King to take indefinite leave; Carlo Broos appointed interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Wade King steps down effective Sept 30, 2024 for family reasons; plans indefinite leave.","Carlo Broos, SVP of Finance since 2024 and company veteran since 2011, named interim CFO.","Broos previously held finance roles at Syngenta and Deloitte; is a registered accountant in Netherlands.","Upon return from leave, King expected to assume newly created Chief Risk Officer role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209767,"accession_number":"0001628280-24-036131","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cibus reports Q2 net loss of $28.5M; cash $30M; sees runway into Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $28.5M ($1.14 loss per share) vs $20.5M loss in year-ago period (not comparable due to merger).","Cash and cash equivalents $30M; expects to fund operations into Q4 2024 without additional financing.","R&D expense $13.0M (+55% YoY); SG&A $9.3M (-16% YoY).","Commercial progress: signed fourth rice HT trait customer FEDEARROZ; Wheat platform operational; Sclerotinia and NUE edits achieved in canola.","Regulatory advances in Canada, UK, EU; IP expanded across 10 trait families."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":1383000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227955,"accession_number":"0001193125-24-160319","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cibus raises ~$13M in direct offering; CEO invests at $10.20/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$12.98M from sale of 1,298,040 shares and warrants at $10.00 per unit; CEO purchased at $10.20 per unit.","Common warrants exercisable at $10.00 (CEO $10.07), expire June 13, 2029; redeemable after soybean platform announcement and stock above $20 for 15 days.","Offering expected to close June 13, 2024; 60-day lock-up on equity issuance and insider sales.","Placement agent A.G.P. receives fee of 6% on most sales, 3% on certain others; no fee on CEO purchase.","Shares and warrants issued under effective shelf registration statement on Form S-3 (File No. 333-273062)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227954,"accession_number":"0001628280-24-026561","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cibus shareholders re-elect six directors, approve executive pay and auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Rory Riggs, Peter Beetham, Mark Finn, Jean-Pierre Lehmann, Gerhard Prante, and Keith Walker re-elected as directors.","Advisory vote on named executive officer compensation approved with 11,222,307 for vs 30,050 against.","Ratification of BDO USA as independent auditor for 2024 approved with 15,792,675 for vs 6,239 against.","Quorum of 63.85% achieved with 15,812,850 shares present out of 24,765,315 outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227953,"accession_number":"0001628280-24-022216","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cibus Q1 net loss $27.0M; cash runway into Q3 2024; EU regulatory progress and wheat platform breakthrough","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $27.0M ($1.12 per share) vs $5.4M in prior period; year-over-year not comparable due to business combination.","Cash and equivalents $24.5M; existing funds expected to cover operations only into Q3 2024 without new financing.","R&D expense $12.0M (up $9.8M) and SG&A $7.0M (up $4.7M), driven by headcount, stock comp, and facility costs.","EU Parliament voted to support NGT regulation similar to conventional breeding; wheat single-cell regeneration completed.","Signed three rice trait agreements (Loveland Products, Interoc); soybean platform expected operational in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":545000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246718,"accession_number":"0001628280-24-012559","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cibus files unaudited pro forma combined 2023 statement reflecting May 2023 merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pro forma combined net loss attributable to company: $295.8M; basic EPS loss $11.13 per share.","Purchase price of Cibus Global transaction: $634.8M, with $585.3M goodwill and $135.4M intangibles recorded.","Combined 2023 revenue: $2.3M; operating expenses $351.1M (includes $249.4M goodwill impairment).","Historical Cibus (Calyxt) net loss $267.6M; Cibus Global historical net loss $35.1M for five months pre-merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246717,"accession_number":"0001628280-24-012521","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cibus Q4 net loss $277M on $249M goodwill impairment; cash $32.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $277.2M ($12.59/share) vs $2.8M prior year, driven by $249.4M non-cash goodwill and intangible impairment.","Cash $32.7M at Dec 31, 2023; expects to fund operations into early Q3 2024.","R&D expense $14.2M, SG&A $6.8M, both up significantly from prior year due to merger and headcount.","Business progress: PSR in Canola transferred to 10 customers; HT traits in Rice with Bayer, Nutrien, Nuseed, Interoc.","EU Parliament vote supporting new genomic techniques; opened gene editing production facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246716,"accession_number":"0001193125-24-063755","cik":1705843,"company_name":"Cibus, Inc.","ticker":"CBUS","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["2.02","2.06","8.01"],"status":"ready","headline":"Cibus estimates $249.4M non-cash impairment charge on goodwill and IPR&D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Goodwill impairment of $150.4M and in-process R&D impairment of $99.0M for fiscal 2023.","Total non-cash impairment charge of ~$249.4M, related to assets from Cibus Global merger.","Triggered by qualitative factors including stock price decline, macro conditions, and development progress.","Preliminary and unaudited; subject to change upon completion of 10-K and audit by BDO USA.","Company expects no current or future cash expenditures from the impairments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":111444186.61333331,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}